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The newly synthesized molecule Metavert was recently
introduced as a promising new agent for treatment of pancreatic
ductal adenocarcinoma (PDAC) [1]. Metavert slows tumor growth
and metastasis by inhibiting both glycogen synthase kinase 3
beta (GSK3B) and histone deacetylases (HDACs). Edderkaoui et al.
recently demonstrated that dual targeting of these pathways
induces synergistic PDAC killing [1], and showed that Metavert
decreases expression of cancer stemness markers associated with
epithelial-to-mesenchymal transition and metastasis, which can
still occur under inhibition of GSK3B alone [2]. However, an
unexpected increase in b-catenin protein levels was seen in
Metavert-treated PDAC cells, suggesting activation of Wnt/b-
catenin signaling. Wnt/b-catenin signaling is complex and was
shown to enhance PDAC development and malignancy [3e6].
However, it has also been suggested that b-catenin partly medi-
ates killing effects of GSK3B inhibitors in KRAS-dependent tu-
mors [7]. Furthermore, a specific dosage of b-catenin signaling is
needed for tumor formation as an excessive accumulation of b-
catenin leads to apoptosis in normal and carcinoma cells [8e10].
Thus, to what extent Wnt/b-catenin signaling plays a role in
Metavert-mediated PDAC killing remains unclear. We therefore
investigated the activity of this pathway upon inhibition of GSK3
and/or HDAC and determined its role in PDAC cell cytotoxicity.* Corresponding author.Department of Gastroenterology and Hepatology, Eras-
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MTT test. BxPC-3, Panc-1, and MIAPaCa-2 cell lines were treated
with GSK3B inhibitors CHIR99021 and TWS119, HDAC inhibitor
Vorinostat orWnt3a conditionedmedium.MTT test was performed
after 72 h [11].
b-Catenin Reporter Assays were performed as described [12].
After transfection with Wnt Responsive Element (WRE) or Mutant
Responsive Element (MRE) vectors and TK-Renilla, luciferase ac-
tivity was measured and normalized for transfection efficiency
using the Dual Luciferase Reporter Assay system (Promega). WRE/
MRE ratios are shown.
qPCR for Axin2 was performed as described [13]. In short, after
24 h of treatment total RNA was isolated for cDNA preparation.
Primers used: forward TATCCAGTGATGCGCTGAC, reverse
TTACTGCCCACACGATAAGG.
siRNA-mediated gene knock-down. Smartpool ON-TARGETplus
siRNAs targeting CTNNB1 and nontargeting siRNA control #2
were introduced into cells using DharmaFECT. Successful
knockdown was confirmed by Western blot analysis [14] using a
b-catenin antibody (#610154, BD Transduction Laboratories) and
IRdye-linked secondary antibodies. b-actin served as loading
control.
Statistics. One-way ANOVA was used for statistical analysis of
MTT, two-way ANOVA and student t-test was used for reporter
assay and knockdown experiment. For dose-response curves,
best fit sigmoidal dose-response (variable slope) curves are
presented.aling does not affect survival of pancreatic cancer cells during dual
an.2019.12.019
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The b-catenin reporter assay showed that while the HDAC
inhibitor Vorinostat alone does not change b-catenin signaling in
PDAC cells (Fig. 1A, B, 1C), the GSK3B inhibitor CHIR99021 acti-
vates this pathway in a dose dependent fashion, far exceeding b-
catenin signaling induced by Wnt-3a conditioned medium.
Importantly, dual targeting of GSK3B and HDAC causes syner-
gistic b-catenin activation as compared to CHIR99021 alone.
Furthermore, in line with previous reports [15e17], the less
potent GSK3B inhibitor TWS119 showed lower activation of b-
catenin signaling (Fig. 1, Supplementary Fig. 1), but neverthelessFig. 1. Treatment of Panc-1 (A, D), MIAPaCa-2 (B, E), BxPC3 (C, F) cells with GSK3B inhi
Vorinostat shows synergistic effect of these inhibitors on b-catenin signaling as determine
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BxPC-3 cells in combination with HDAC inhibition. Vorinostat
also strengthens this signal in combination with Wnt-3a condi-
tioned medium. We verified these findings by investigation of
mRNA levels of AXIN2, a downstream target gene of b-catenin
(Fig. 1D, E, 1F). Similar to CHIR99021, albeit at lower levels,
TWS119 increases expression of AXIN2 alone and in combination
with Vorinosat in all three cell lines.
We next investigated whether this synergistic b-catenin
signaling mediates PDAC cell killing. First we confirmed the effect
of combined inhibition of GSK3B and HDAC on PDAC growth
inhibition (Fig. 2). Subsequently, we tested whether b-cateninbitors CHIR99021 (CH) and TWS119 (TW) or their combination with HDAC inhibitor
d by reporter assays or qPCR for AXIN2. Mean ± SEM, *p < 0.05.
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Fig. 2. Treatment with CHIR99021, TWS119, Vorinostat or their combination induces killing of Panc-1 (A, D), MIAPaCa-2 (B, E), BxPC3 (C, F) cells as determined by MTT assay
(Mean ± SEM) (B).
K. Nesteruk et al. / Pancreatology xxx (xxxx) xxx 3signaling affects PDAC growth by addition of Wnt-3a conditioned
medium, as activation of Wnt3a receptors Frizzled and LRP5/6
leads to stabilization of cytoplasmic b-catenin [18]. However,
Wnt3a stimulation did not affect PDAC cell viability (Fig. 3).
We then studied the direct effect of b-catenin through verifiedFig. 3. Wnt-3a-conditioned medium does not affect cell viability as determined by
MTT assay (Mean ± SEM).
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catenin in itself decreased the growth of pancreatic cancer cell
lines by 22% (Panc-1), 33% (MIAPaCa-2) and 20% (BxPC-3)(not
shown, p < 0.05), knockdown did not affect susceptibility of
Panc-1 and MIAPaCa-2 to treatment of GSK3B and HDAC inhibi-
tor, and only slightly increased survival of BxPC-3 compared to
controls when treated with CHIR99021 and Vorinostat (Fig. 4D).Discussion
Our data suggest that while b-catenin knockdown in itself may
reduce PDAC viability to some extent, activation of this signaling
pathway does not contribute to the cytotoxic effects induced by
combined GSK3/HDAC inhibition. It is conceivable that the syner-
gistic b-catenin signaling triggered by these inhibitors seen here
mediates other anti-tumorigenic effects of this dual treatment i.e.
EMT or metastasis. The exact role of b-catenin signaling during
Metavert treatment of PDAC remains elusive and requires further
investigation.aling does not affect survival of pancreatic cancer cells during dual
an.2019.12.019
Fig. 4. Knockdown of b-catenin by siRNA (A) does not affect survival of Panc-1 (B) and MIAPaCa-2 (C) cells after treatment with CHIR99021 (CH), TWS119 and Vorinostat and
moderately inhibits cell killing of BxPC-3 (D) cells by CH and CH þ Vorinostat (Mean ± SEM, *p < 0.05).
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